Medicines, 2020
Shortlist up to four to read them side by side.
1,035 medicine recalls FDA’s Enforcement Report published in 2020, newest first; 18,075 in all since 2012.
FDA’s medicine recalls, as its Enforcement Report classifies them, from June 2012. Lists of FDA’s records can’t be saved for alerts: openFDA asks that its data not be used to alert the public (openFDA); FDA’s own emails do that. Copied Nov 6, 2026.
1,035of 1,035 medicine recallsshown with your filters
The list
- Medicine recall Glenmark Ranitidine Tablets USP 150 mg CGMP Deviations: Presence of NDMA impurity detected in product. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusOngoingWhereNo state named
- Medicine recall Glenmark Ranitidine Tablets USP 150 mg CGMP Deviations: Presence of NDMA impurity detected in product. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusOngoingWhereNo state named
- Medicine recall Glenmark Ranitidine Tablets USP 300 mg CGMP Deviations: Presence of NDMA impurity detected in product. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusOngoingWhereNo state named
- Medicine recall Glenmark Ranitidine Tablets USP 300 mg CGMP Deviations: Presence of NDMA impurity detected in product. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusOngoingWhereNo state named
- Medicine recall Glenmark Ranitidine Tablets USP 300 mg CGMP Deviations: Presence of NDMA impurity detected in product. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusOngoingWhereNo state named
- Medicine recall Glenmark Ranitidine Tablets USP 150 mg CGMP Deviations: Presence of NDMA impurity detected in product. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusOngoingWhereNo state named
- Medicine recall Ranitidine 150 mg tablets, 24 count bottles CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusTerminatedWhereNo state named
- Medicine recall Ranitidine 150 mg tablets, 130 count bottles CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusTerminatedWhereNo state named
- Medicine recall Ranitidine Capsules 300 mg, 30 count bottles CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusTerminatedWhereNo state named
- Medicine recall Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05) CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNot namedno state, in where it went PublishedJan 15, 2020ClassClass IIStatusTerminatedWhereNo state named
- Medicine recall Estriol, USP, (Micronized), 0.06 g Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportCaliforniathe one state its words name PublishedJan 15, 2020ClassClass IIStatusTerminatedWhereCalifornia
- Medicine recall Estriol, USP, (Micronized), 0.12 g Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportCaliforniathe one state its words name PublishedJan 15, 2020ClassClass IIStatusTerminatedWhereCalifornia
- Medicine recall Estriol, USP, (Micronized), 0.24 g Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results. Class IIFDA’s classJan 15, 2020in FDA’s Enforcement ReportCaliforniathe one state its words name PublishedJan 15, 2020ClassClass IIStatusTerminatedWhereCalifornia
- Medicine recall SURE 48 hr Confidence Unscented invisible solid Anti-Perspirant & Deodorant Labeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product. Class IIIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 15, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall SURE 48hr Confidence Nourishing Coconut invisible solid Antiperspirant & Deodorant Labeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product. Class IIIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 15, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall SURE 48hr Confidence Regular Original Solid Anti-Perspirant & Deodorant Labeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product. Class IIIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 15, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall SURE 48hr Confidence Unscented Original Solid Anti-Perspirant & Deodorant Labeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product. Class IIIFDA’s classJan 15, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 15, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall Ranitidine Syrup (Ranitidine Oral Solution USP), 15 mg/mL, 150 mg/10 mL per cup CGMP Deviations: Presence of NDMA impurity detected in product. Class IIFDA’s classJan 8, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 8, 2020ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall RANITIDINE TABLETS, USP 150mg, 10,000-count bag, Country of Origin: INDIA CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class IIFDA’s classJan 8, 2020in FDA’s Enforcement Report3 statesnamed in where it went PublishedJan 8, 2020ClassClass IIStatusOngoingWhereNew Jersey, New York and Oregon
- Medicine recall Silver Bullet, Get Bigger and Harder, Works in Minutes, Lasts for Days, 10 male enhancement capsules in… Marketed Without an Approved NDA/ANDA; Product contains undeclared active ingredient - Sildenafil. FDA Class I, its most serious class Class IFDA’s class (needs attention)Jan 8, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 8, 2020ClassClass IStatusTerminatedWhereNationwide
- Medicine recall PCA Skin Blemish Control Bar, 3.2 oz/90g, Salicylic acid 2% - Acne cleanser, For external use only Superpotent Drug: Salicylic acid content is above the firm’s specification. Class IIIFDA’s classJan 8, 2020in FDA’s Enforcement ReportArizonathe one state its words name PublishedJan 8, 2020ClassClass IIIStatusTerminatedWhereArizona
- Medicine recall Bimatoprost Ophthalmic Solution, 0.03%, For Use in the Eyes Only, Sterile Failed Impurities/Degradation Specifications: Out-of-specification result observed in any other individual impurity. Class IIIFDA’s classJan 8, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 8, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall MYORISAN (isotretinoin capsules, USP), 20mg Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg… Class IIFDA’s classJan 8, 2020in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedJan 8, 2020ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall NORepinephrine Bitartrate 8 mg added to 250 mL 5% Dextrose Injection USP Subpotent Drug Class IIIFDA’s classJan 1, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 1, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall NORepinephrine Bitartrate 8 mg added to 500 mL 5% Dextrose Injection USP Subpotent Drug Class IIIFDA’s classJan 1, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 1, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall NORepinephrine Bitartrate 4 mg added to 250 mL 5% Dextrose Injection USP Subpotent Drug Class IIIFDA’s classJan 1, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 1, 2020ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall Estriol [(16a, 17B)-Estra-1,3,5(10)-triene-3,16,17-triol Subpotent Drug: Supplier indicated assay results did not meet specifications. Class IIFDA’s classJan 1, 2020in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJan 1, 2020ClassClass IIStatusTerminatedWhereNationwide
Nothing matches all of these.
Remove a filter to see more. Each one is a fact FDA’s record publishes, so a recall can be left out because its record is silent on it.
Source:
FDA, Drug recall enforcement reports. Released Nov 3, 2026. Updated weekly.
Recalls of food, medicines, medical devices, pet food and animal drugs are from the U.S. Food and Drug Administration (FDA). FDA does not endorse Hearth Record. openFDA: “Do not rely on openFDA to make decisions regarding medical care.”
Your shortlist0 of 4
Add one more to compare.